Cart
sales@molnova.com
ETHOTOIN
CAS No. 86-35-1
ETHOTOIN( —— )
Catalog No. M37710 CAS No. 86-35-1
Ethotoin (Peganone), an orally active anticonvulsant agent utilized in epilepsy research, is a hydantoin derivative analogous to phenytoin .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 37 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 140 | In Stock |
|
| 50MG | 230 | In Stock |
|
| 100MG | 369 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameETHOTOIN
-
NoteResearch use only, not for human use.
-
Brief DescriptionEthotoin (Peganone), an orally active anticonvulsant agent utilized in epilepsy research, is a hydantoin derivative analogous to phenytoin .
-
DescriptionEthotoin (Peganone), an orally active anticonvulsant agent utilized in epilepsy research, is a hydantoin derivative analogous to phenytoin .
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number86-35-1
-
Formula Weight204.23
-
Molecular FormulaC11H12N2O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCN1C(=O)NC(C1=O)C1=CC=CC=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
(S,R,S)-AHPC TFA
(S,R,S)-AHPC TFA (VH032-NH2 TFA) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein.
-
Stresscopin-Related ...
Stresscopin-related peptide (human) is a specific ligand for the type 2 CRH receptor. Stresscopin-related peptide (human) suppresses food intake, delayed gastric emptying and decreases heat-induced edema. Stresscopin-related peptide (human) maintains homeostasis after stress, and can be used in the research of stress-related diseases.
-
AD 01
FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration as well as tubule and microvessel formation in vitro and in vivo. Blocks tumor growth in xenograft models.
